Sandoz Group AG (SDZNY) 股票价格预测

Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. The company is headquartered in Basel, Basel-Stadt and currently employs 23,567 full-time employees. The company went IPO on 2023-10-04. The firm operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The firm serves customers worldwide.